Powerful relief to allow you to quickly tackle even your toughest cravings. NiQuitin Lozenges offer powerful relief and allow you to quickly tackle even your toughest cravings, as and when they happen. They let you control when you get your nicotine. They're easy to keep handy, discreet to use, and come in two flavours - original and mint. The strength of lozenge you use depends on when you have your first cigarette of the day. If you tend to light up within 30 minutes of waking up, you'll need NiQuitin 4mg Lozenges. If you start more than 30 minutes after waking, you'll need NiQuitin 2mg Lozenges. Then: For Step 1, you'll probably need a lozenge every one to two hours, and at least 9 lozenges a day up to a maximum of 15. After six weeks you'll be ready to move on to Step 2, and need one lozenge every two to four hours. Then after nine weeks, you should be down to one lozenge every four to eight hours. Following the step-down programme in this way will let you gradually wean yourself off nicotine so you can quit for good. 2mg is suitable for people who smoke more than 30 minutes after waking up, 4mg is suitable for those who smoke within 30 minutes of waking up.

Suitable For :

Information Currently Unavailable

How to Use :

NiQuitin 4 mg Mint or Original Lozenges are suitable for smokers who have their first cigarette of the day within 30 minutes of waking up.

NiQuitin 2 mg Mint or Original Lozenges are suitable for smokers who have their first cigarette of the day afer 30 minutes of waking up.

One lozenge should be placed in the mouth and allowed to dissolve. Periodically, the lozenge should be moved from one side of the mouth to the other, and repeated, until the lozenge is completely dissolved (approximately 20 - 30 minutes). The lozenge should not be chewed or swallowed whole.

Users should not eat or drink while a lozenge is in the mouth.

Behavioural therapy, advice & support will normally improve the success rate.

Adults (18 years and over):

Abrupt cessation of smoking:

Users should make every effort to stop smoking completely during treatment with NiQuitin Mint or Original Lozenges.

Recommended treatment schedule:

Step 1 - Weeks 1 to 6 (Initial treatment period)

- 1 lozenge every 1 to 2 hours

Step 2 - Weeks 7 to 9 (Step down treatment period)

- 1 lozenge every 2 to 4 hours

Step 3 - Weeks 10 to 12 (Step down treatment period)

- 1 lozenge every 4 to 8 hours

During weeks 1 to 6 it is recommended that users take a minimum of 9 lozenges per day. Users should not exceed 15 lozenges per day.

To help stay smoke free beyond 12 weeks, users may take 1-2 lozenges per day only on occasions when they are strongly tempted to smoke.

Those who use the lozenges beyond 9 months are recommended to seek additional help and advice from a healthcare professional.

KEEP ALL MEDICINS OUT OF REACH AND SIGHT OF CHILDREN.

PLEASE READ ALL PRODUCT PACKAGING AND LABELS PRIOR TO USE.

Storage :

Information Currently Unavailable

Precautions :

The risks associated with the use of Nicotine Replacement Therapy (NRT) are substantially outweighed in virtually all circumstances by the well established dangers of continued smoking.

Patients hospitalised for MI, severe dysrhythmia or CVA who are considered to be haemodynamically unstable:

Should be encouraged to stop smoking with non-pharmacological interventions. If this fails, NiQuitin Mint or Original Lozenges may be considered, but as data on safety in this patient group are limited, initiation should only be under medical supervision. Once patients are discharged from hospital they can use NRT as normal.

Diabetes Mellitus:

Patients with diabetes mellitus should be advised to monitor their blood sugar levels more closely than usual when NRT is initiated as catecholamines released by nicotine can affect carbohydrate metabolism

Allergic reactions:

Susceptibility to angioedema and urticaria

A risk-benefit assessment should be made by an appropriate healthcare professional for patients with the following conditions:

Renal and hepatic impairment:

Use with caution in patients with moderate to severe hepatic impairment and/or severe renal impairment as the clearance of nicotine or its metabolites may be decreased with the potential for increased adverse effects.

Phaeochromocytoma and uncontrolled hyperthyroidism:

Use with caution in patients with uncontrolled hyperthyroidism or phaeochromocytoma as nicotine causes release of catecholamines.

GI disease

Swallowed nicotine may exacerbate symptoms in patients suffering from oesophagitis, gastric or peptic ulcers and oral NRT preparations should be used with caution in these conditions. Ulcerative stomatitis has been reported.

Danger in small children:

Doses of nicotine tolerated by adult and adolescent smokers can produce severe toxicity in small children that may be fatal. Products containing nicotine should not be left where they may be misused, handled or ingested by children.

Stopping smoking:

Polycyclic aromatic hydrocarbons in tobacco smoke induce the metabolism of drugs catalysed by CYP 1A2 (and possibly by CYP 1A1). When a smoker stops this may result in a slower metabolism and a consequent rise in blood levels of such drugs.

Transferred dependence:

Transferred dependence is rare and is both less harmful and easier to break than smoking dependence.

Phenylketonuria:

NiQuitin Mint or Original Lozenges contain a source of phenylalanine equivalent to 3mg/dose. May be harmful for people with phenylketonuria.

Sodium content:

Each NiQuitin Mint or Original Lozenge contains 15 mg of sodium. People on a low sodium diet should take this into account.

KEEP ALL MEDICINES OUT OF REACH AND SIGHT OF CHILDREN.

PLEASE READ ALL PRODUCT PACKAGING AND LABELS PRIOR TO USE

Ingredients :

NiQuitin 4 mg Mint Lozenges contain 4 mg Nicotine in the form of a resin complex (nicotine polacrilex 22.2 mg).

NiQuitin 2 mg Mint Lozenges contain 2 mg Nicotine in the form of a resin complex (nicotine polacrilex 11.1 mg).

Other ingredients

Mannitol (E421), sodium alginate, xanthan gum, potassium bicarbonate, calcium polycarbophil, sodium carbonate, aspartame (E951), 

Attachments : 

Information Currently Unavailable